Literature DB >> 6262377

Pyruvate dehydrogenase complex activity in normal and deficient fibroblasts.

K F Sheu, C W Hu, M F Utter.   

Abstract

Pyruvate dehydrogenase complex (PDC) activity in human skin fibroblasts appears to be regulated by a phosphorylation-dephosphorylation mechanism, as is the case with other animal cells. The enzyme can be activated by pretreating the cells with dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase, before they are disrupted for measurement of PDC activity. With such treatment, the activity reaches 5-6 nmol/min per mg of protein at 37 degrees C with fibroblasts from infants. Such values represent an activation of about 5-20-fold over those observed with untreated cells. That this assay, based on [1-(14)C]pyruvate decarboxylation, represents a valid measurement of the overall PDC reaction is shown by the dependence of (14)CO(2) production on the presence of thiamin-PP, coenzyme A (CoA), Mg(++), and NAD(+). Also, it has been shown that acetyl-CoA and (14)CO(2) are formed in a 1:1 ratio. A similar degree of activation of PDC can also be achieved by adding purified pyruvate dehydrogenase phosphatase and high concentrations of Mg(++) and Ca(++), or in some cases by adding the metal ions alone to the cell homogenate after disruption. These results strongly suggest that activation is due to dephosphorylation. Addition of NaF, which inhibits dephosphorylation, leads to almost complete loss of PDC activity. Assays of completely activated PDC were performed on two cell lines originating from patients reported to be deficient in this enzyme (Blass, J. P., J. Avigan, and B. W. Ublendorf. 1970. J. Clin. Invest. 49: 423-432; Blass, J. P., J. D. Schuman, D. S. Young, and E. Ham. 1972. J. Clin. Invest. 51: 1545-1551). Even after activation with DCA, fibroblasts from the patients showed values of only 0.1 and 0.3 nmol/min per mg of protein. A familial study of one of these patients showed that both parents exhibited activity in fully activated cells about half that of normal values, whereas cells from a sibling appeared normal. These results demonstrate the inheritance nature of PDC deficiency, and that the present assay is sufficient to detect the heterozygous carriers of the deficiency. Application of the same procedures to fibroblasts obtained from 16 individuals who were believed to have normal PDC activities showed a range from about 2-2.5 nmol/min per mg protein for adults to 5-6 nmol/min per mg protein for cells from infants.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6262377      PMCID: PMC370714          DOI: 10.1172/jci110176

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Regulation of pyruvate dehydrogenase and pyruvate dehydrogenase phosphate phosphatase activity in rat epididymal fat-pads. Effects of starvation, alloxan-diabetes and high-fat diet.

Authors:  D Stansbie; R M Denton; B J Bridges; H T Pask; P J Randle
Journal:  Biochem J       Date:  1976-01-15       Impact factor: 3.857

Review 2.  Disorders of pyruvate metabolism.

Authors:  J P Blass
Journal:  Neurology       Date:  1979-03       Impact factor: 9.910

3.  Regulation of pyruvate dehydrogenase kinase and phosphatase by acetyl-CoA/CoA and NADH/NAD ratios.

Authors:  F H Pettit; J W Pelley; L J Reed
Journal:  Biochem Biophys Res Commun       Date:  1975-07-22       Impact factor: 3.575

4.  Regulation of pyruvate dehydrogenase in heart mitochondria.

Authors:  R Portenhauser; O H Wieland; H Wenzel
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1977-06

5.  Partial purification and characterization of a pyruvate dehydrogenase-complex-inactivating enzyme from rat liver.

Authors:  A Lynen; E Sedlaczek; O H Wieland
Journal:  Biochem J       Date:  1978-02-01       Impact factor: 3.857

6.  Clinical studies of a patient with pyruvate decarboxylase deficiency.

Authors:  J P Blass; A P Kark; W K Engel
Journal:  Arch Neurol       Date:  1971-11

7.  Relationshiop between phosphorylation and activity of pyruvate dehydrogenase in rat liver mitochondria and the absence of such a relationship for pyruvate carboxylase.

Authors:  A B Leiter; M Weinberg; F Isohashi; M F Utter
Journal:  J Biol Chem       Date:  1978-04-25       Impact factor: 5.157

8.  Pyruvate dehydrogenase deficiency in spinocerebellar degenerations.

Authors:  R A Kark; M Rodriguez-Budelli
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

9.  Thiamine dependency in a patient with congenital lacticacidaemia due to pyruvate dehydrogenase deficiency.

Authors:  H Wick; K Schweizer; R Baumgartner
Journal:  Agents Actions       Date:  1977-09

10.  Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids.

Authors:  S Whitehouse; R H Cooper; P J Randle
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

View more
  47 in total

1.  A case of PDH-E1 alpha mosaicism in a male patient with severe metabolic lactic acidosis.

Authors:  A Seyda; K Chun; S Packman; B H Robinson
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

2.  A four-nucleotide insertion at the E1 alpha gene in a patient with pyruvate dehydrogenase deficiency.

Authors:  H Endo; S Miyabayashi; K Tada; K Narisawa
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Multiple presentation of mitochondrial disorders.

Authors:  A Nissenkorn; A Zeharia; D Lev; A Fatal-Valevski; V Barash; A Gutman; S Harel; T Lerman-Sagie
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

4.  Modulation by dexamethasone of the pyruvate dehydrogenase-complex activity in 3T3-L1 adipocytes.

Authors:  M S Patel; C Raefsky; C W Hu; L Ho
Journal:  Biochem J       Date:  1985-03-01       Impact factor: 3.857

5.  Defective gene in lactic acidosis: abnormal pyruvate dehydrogenase E1 alpha-subunit caused by a frame shift.

Authors:  H Endo; K Hasegawa; K Narisawa; K Tada; Y Kagawa; S Ohta
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

6.  Mitochondrial abnormalities in fibroblast line GM3093 defective in oxidative metabolism.

Authors:  G Constantopoulos; M A Greenwood; S H Sorrell
Journal:  Experientia       Date:  1986-03-15

7.  Defective intramitochondrial NADH oxidation in skin fibroblasts from an infant with fatal neonatal lacticacidemia.

Authors:  B H Robinson; N McKay; P Goodyer; G Lancaster
Journal:  Am J Hum Genet       Date:  1985-09       Impact factor: 11.025

8.  Thiamin-responsive maple-syrup-urine disease: decreased affinity of the mutant branched-chain alpha-keto acid dehydrogenase for alpha-ketoisovalerate and thiamin pyrophosphate.

Authors:  D T Chuang; L S Ku; R P Cox
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

9.  Deficiency of the iron-sulfur clusters of mitochondrial reduced nicotinamide-adenine dinucleotide-ubiquinone oxidoreductase (complex I) in an infant with congenital lactic acidosis.

Authors:  R W Moreadith; M L Batshaw; T Ohnishi; D Kerr; B Knox; D Jackson; R Hruban; J Olson; B Reynafarje; A L Lehninger
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

10.  A Korean female patient with thiamine-responsive pyruvate dehydrogenase complex deficiency due to a novel point mutation (Y161C)in the PDHA1 gene.

Authors:  Eun-Ha Lee; Mi-Sun Ahn; Jin-Soon Hwang; Kyung-Hwa Ryu; Sun-Jun Kim; Sung-Hwan Kim
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.